55 results
Page 2 of 3
8-K
EX-99.1
2lgd66 k8gvau
7 Jan 19
Results of Operations and Financial Condition
7:13am
8-K
EX-99.1
4uopy3uv
29 Nov 18
Alkermes Announces Positive Topline Results FromENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia
7:17am
8-K
EX-99.1
5flm9v
2 Nov 18
Regulation FD Disclosure
12:00am
8-K
EX-99.1
fspxp
23 Oct 18
Results of Operations and Financial Condition
8:15am
8-K
EX-99.1
eh5 l05jv
26 Jul 18
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
m0zqk1m2u8vz9504rood
2 Jul 18
Regulation FD Disclosure
7:14am
8-K
EX-99.1
2k2 xc21pro215emu2qd
26 Apr 18
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
y0sz9
27 Nov 17
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
kb0k1sf ej
20 Oct 16
Regulation FD Disclosure
12:00am
8-K
EX-99.1
lyele1ts8t9bjzp oogc
8 Apr 14
Alkermes Announces Positive Topline Results from Pivotal Phase 3 Study of Aripiprazole Lauroxil for Treatment of Schizophrenia
12:00am
10-KT
sadj8fwnd 4mws6ri
27 Feb 14
Annual report (with FYE transition)
12:00am
8-K
EX-99.1
vxurm4 q7fl8a
8 Jan 14
Alkermes Announces Advances with Its Late-stage CNS Pipeline
12:00am
8-K
EX-99.1
4g4e22
6 Jan 14
Alkermes Announces Notice of Allowance of U.S. Patent for a Novel Fumarate Prodrug for Multiple Sclerosis
12:00am